Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More
HTML-код
- Опубликовано: 8 фев 2025
- Laura Jones an the approval of gefitinib for EGFR-mutant lung cancer, results from a phase II study of atezolizumab in bladder cancer, and new treatment advancements in multiple myeloma.